

Peter P Toth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/387906/publications.pdf>

Version: 2024-02-01

257
papers

12,782
citations

22153

59
h-index

30922

102
g-index

262
all docs

262
docs citations

262
times ranked

13624
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid Profile. JAMA - Journal of the American Medical Association, 2013, 310, 2061.	7.4	568
2	Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. Journal of Clinical Lipidology, 2011, 5, 133-140.	1.5	483
3	Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. Journal of Clinical Lipidology, 2011, 5, S1-S8.	1.5	406
4	Friedewald-Estimated Versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications. Journal of the American College of Cardiology, 2013, 62, 732-739.	2.8	331
5	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. International Journal of Cardiology, 2014, 171, 309-325.	1.7	316
6	Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Archives of Medical Science, 2015, 1, 1-23.	0.9	311
7	Familial Hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of Clinical Lipidology, 2011, 5, S9-S17.	1.5	292
8	High-density lipoproteins: A consensus statement from the National Lipid Association. Journal of Clinical Lipidology, 2013, 7, 484-525.	1.5	276
9	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Nutrition Reviews, 2017, 75, 731-767.	5.8	238
10	Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. Journal of Clinical Lipidology, 2011, 5, 338-367.	1.5	235
11	Prevalence of lipid abnormalities in the United States: The National Health and Nutrition Examination Survey 2003–2006. Journal of Clinical Lipidology, 2012, 6, 325-330.	1.5	206
12	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Archives of Medical Science, 2017, 5, 965-1005.	0.9	206
13	Ezetimibe therapy: mechanism of action and clinical update. Vascular Health and Risk Management, 2012, 8, 415.	2.3	169
14	Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. BMC Medicine, 2015, 13, 229.	5.5	169
15	Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 101161ATV0000000000000153.	2.4	167
16	Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vascular Health and Risk Management, 2016, 12, 171.	2.3	166
17	Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. International Journal of Cardiology, 2016, 225, 184-196.	1.7	155
18	Analysis of vitamin D levels in patients with and without statin-associated myalgia – A systematic review and meta-analysis of 7 studies with 2420 patients. International Journal of Cardiology, 2015, 178, 111-116.	1.7	154

#	ARTICLE	IF	CITATIONS
19	Residual macrovascular risk in 2013: what have we learned?. Cardiovascular Diabetology, 2014, 13, 26.	6.8	149
20	Statin therapy and plasma coenzyme Q10 concentrationsâ€”A systematic review and meta-analysis of placebo-controlled trials. Pharmacological Research, 2015, 99, 329-336.	7.1	145
21	HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative. European Heart Journal, 2015, 36, 22-30.	2.2	142
22	Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis, 2016, 253, 194-208.	0.8	142
23	Inflammation and cardiovascular disease: From mechanisms to therapeutics. American Journal of Preventive Cardiology, 2020, 4, 100130.	3.0	142
24	Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. Atherosclerosis, 2015, 241, 433-442.	0.8	139
25	Management of Statin Intolerance in 2018: Still More Questions Than Answers. American Journal of Cardiovascular Drugs, 2018, 18, 157-173.	2.2	130
26	Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies. Journal of the American Heart Association, 2016, 5, .	3.7	121
27	Statin intolerance â€” an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opinion on Drug Safety, 2015, 14, 935-955.	2.4	117
28	High-Density Lipoprotein and Cardiovascular Risk. Circulation, 2004, 109, 1809-1812.	1.6	113
29	Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clinical Therapeutics, 2004, 26, 1355-1367.	2.5	109
30	Vitamin D supplementation and incident preeclampsia: A systematic review and meta-analysis of randomized clinical trials. Clinical Nutrition, 2020, 39, 1742-1752.	5.0	106
31	Natural approaches in metabolic syndrome management. Archives of Medical Science, 2018, 14, 422-441.	0.9	103
32	Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2020, 323, 1565.	7.4	103
33	Prevalence of dyslipidemia and associated risk factors in Turkish adults. Journal of Clinical Lipidology, 2014, 8, 206-216.	1.5	99
34	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. Journal of Clinical Lipidology, 2014, 8, 148-172.	1.5	98
35	Trends in Lipids, Obesity, Metabolic Syndrome, and Diabetes Mellitus in the United States: An NHANES Analysis (2003â€”2004 to 2013â€”2014). Obesity, 2019, 27, 309-314.	3.0	94
36	C-reactive protein and risk of cardiovascular disease: Evidence and clinical application. Current Atherosclerosis Reports, 2003, 5, 341-349.	4.8	93

#	ARTICLE	IF	CITATIONS
37	Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study. <i>Atherosclerosis</i> , 2015, 242, 243-250.	0.8	93
38	Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study. <i>Frontiers in Pharmacology</i> , 2015, 6, 299.	3.5	92
39	Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapyâ€”A meta-analysis of 11 randomized controlled trials involving 21,295 participants. <i>Pharmacological Research</i> , 2013, 72, 35-44.	7.1	90
40	Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2019, 143, 1-16.	7.1	90
41	Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology. <i>American Journal of Preventive Cardiology</i> , 2020, 1, 100009.	3.0	90
42	Polyphenols: Potential Use in the Prevention and Treatment of Cardiovascular Diseases. <i>Current Pharmaceutical Design</i> , 2018, 24, 239-258.	1.9	87
43	Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology. <i>Annals of Internal Medicine</i> , 2016, 165, 867.	3.9	84
44	Introducing the â€œDruceboâ€™ effect in statin therapy: a systematic review of studies comparing reported rates of statinâ€™associated muscle symptoms, under blinded and openâ€™label conditions. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 1023-1033.	7.3	84
45	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. <i>Atherosclerosis Supplements</i> , 2014, 15, 1-15.	1.2	83
46	Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1152-1160.e2.	1.5	83
47	Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. <i>Kidney International</i> , 2018, 93, 1397-1408.	5.2	83
48	High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Realâ€™World Administrative Claims Analysis of Statinâ€™Treated Patients With High Residual Cardiovascular Risk. <i>Journal of the American Heart Association</i> , 2018, 7, e008740.	3.7	81
49	Systematic Review of Lowâ€™Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	77
50	The â€œGood Cholesterolâ€™. <i>Circulation</i> , 2005, 111, e89-91.	1.6	75
51	The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2012, 11, 109.	6.8	75
52	Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 206-212.	2.2	71
53	<scp>PCSK9</scp> inhibitor access barriersâ€™issues and recommendations: Improving the access process for patients, clinicians and payers. <i>Clinical Cardiology</i> , 2017, 40, 243-254.	1.8	71
54	Reverse cholesterol transport: High-density lipoproteinâ€™s magnificent mile. <i>Current Atherosclerosis Reports</i> , 2003, 5, 386-393.	4.8	69

#	ARTICLE	IF	CITATIONS
55	Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. <i>Circulation</i> , 2017, 135, 1819-1831.	1.6	67
56	Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 453-461.	4.7	64
57	Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 41-49.	1.8	64
58	Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation. <i>Current Atherosclerosis Reports</i> , 2018, 20, 20.	4.8	62
59	Should low high-density lipoprotein cholesterol (HDL-C) be treated?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 353-368.	4.7	61
60	Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2016, 107, 360-371.	7.1	61
61	Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	61
62	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 849-854.	1.8	60
63	Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2016, 103, 236-252.	7.1	60
64	Non-High-Density Lipoprotein Cholesterol, Guideline Targets, and Population Percentiles for Secondary Prevention in 1.3 Million Adults. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1960-1965.	2.8	59
65	Molecular mechanisms of statin intolerance. <i>Archives of Medical Science</i> , 2016, 3, 645-658.	0.9	58
66	Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement. <i>American Journal of Preventive Cardiology</i> , 2022, 10, 100335.	3.0	58
67	Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. <i>Journal of Clinical Lipidology</i> , 2015, 9, 576-582.	1.5	56
68	Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey. <i>Journal of Clinical Lipidology</i> , 2019, 13, 100-108.	1.5	56
69	Coronary heart disease risk: Low-density lipoprotein and beyond. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 181-194.	4.9	56
70	Narrowing Sex Differences in Lipoprotein Cholesterol Subclasses Following Midlife: The Very Large Database of Lipids (VLDL-10B). <i>Journal of the American Heart Association</i> , 2014, 3, e000851.	3.7	54
71	Statins: Then and Now. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 15, 23.	1.0	54
72	Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. <i>Atherosclerosis</i> , 2014, 235, 585-591.	0.8	53

#	ARTICLE	IF	CITATIONS
73	The Therapeutic Role of Niacin in Dyslipidemia Management. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 141-158.	2.0	52
74	Association of types of dietary fats and all-cause and cause-specific mortality: A prospective cohort study and meta-analysis of prospective studies with 1,164,029 participants. <i>Clinical Nutrition</i> , 2020, 39, 3677-3686.	5.0	52
75	Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1966-1976.	1.8	50
76	Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. <i>Journal of Medical Economics</i> , 2017, 20, 555-564.	2.1	49
77	Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis. <i>Lipids in Health and Disease</i> , 2019, 18, 175.	3.0	48
78	Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. <i>Atherosclerosis</i> , 2015, 242, 87-96.	0.8	47
79	Severe hypertriglyceridemia and factors associated with acute pancreatitis in an integrated health care system. <i>Journal of Clinical Lipidology</i> , 2016, 10, 880-890.	1.5	47
80	Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 419-431.	2.6	45
81	Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1670-1680.	3.0	45
82	Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. <i>American Heart Journal</i> , 2019, 217, 72-83.	2.7	45
83	Cardiovascular Risk and Statin Therapy Considerations in Women. <i>Diagnostics</i> , 2020, 10, 483.	2.6	45
84	The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease. <i>Lipids in Health and Disease</i> , 2015, 14, 29.	3.0	44
85	Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014. <i>Diabetes Care</i> , 2019, 42, 2307-2314.	8.6	43
86	Insulin Resistance, Small LDL Particles, and Risk for Atherosclerotic Disease. <i>Current Vascular Pharmacology</i> , 2014, 12, 653-657.	1.7	43
87	Drug Treatment of Hyperlipidaemia. <i>Drugs</i> , 2010, 70, 1363-1379.	10.9	42
88	High-density lipoprotein subfractions: current views and clinical practice applications. <i>Trends in Endocrinology and Metabolism</i> , 2014, 25, 329-336.	7.1	42
89	Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol. <i>Circulation</i> , 2015, 132, 667-676.	1.6	41
90	Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1597-1605.	1.8	41

#	ARTICLE	IF	CITATIONS
91	Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis. Journal of Clinical Lipidology, 2017, 11, 972-985.e9.	1.5	40
92	Very Large Database of Lipids: Rationale and Design. Clinical Cardiology, 2013, 36, 641-648.	1.8	39
93	Combination therapy in dyslipidemia: Where are we now?. Atherosclerosis, 2014, 237, 319-335.	0.8	39
94	Altlix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study. Nutrients, 2019, 11, 2580.	4.1	39
95	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). Progress in Cardiovascular Diseases, 2021, 67, 40-52.	3.1	39
96	Productivity losses associated with cardiovascular disease: a systematic review. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 759-769.	1.4	38
97	Accuracy of low-density lipoprotein cholesterol estimation at very low levels. BMC Medicine, 2017, 15, 83.	5.5	38
98	New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease. European Cardiology Review, 2020, 15, 1-9.	2.2	38
99	Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel. Frontiers in Cardiovascular Medicine, 2021, 8, 787761.	2.4	38
100	Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. Current Medical Research and Opinion, 2013, 29, 435-451.	1.9	36
101	Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo. Lipids in Health and Disease, 2016, 15, 28.	3.0	36
102	Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus. American Journal of Cardiology, 2017, 120, 1521-1527.	1.6	36
103	Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: A VOYAGER analysis. Clinical Biochemistry, 2019, 64, 24-29.	1.9	36
104	Prevalence of US Adults with Triglycerides ≥150 mg/dl: NHANES 2007–2014. Cardiology and Therapy, 2020, 9, 207-213.	2.8	35
105	Step-by-step diagnosis and management of the nocebo/drug effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1596-1622.	7.3	35
106	Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study. Cardiovascular Research, 2019, 115, 204-212.	3.8	34
107	Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study. Metabolites, 2020, 10, 392.	2.9	34
108	Ten things to know about ten cardiovascular disease risk factors – 2022. American Journal of Preventive Cardiology, 2022, 10, 100342.	3.0	34

#	ARTICLE	IF	CITATIONS
109	Update on the efficacy and safety of combination ezetimibe plus statin therapy. <i>Clinical Lipidology</i> , 2010, 5, 655-684.	0.4	33
110	Burden of First and Recurrent Cardiovascular Events Among Patients With Hyperlipidemia. <i>Clinical Cardiology</i> , 2015, 38, 483-491.	1.8	33
111	Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidence. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 279-289.	4.4	33
112	Drug therapy for hypertriglyceridemia: Fibrates and omega-3 fatty acids. <i>Current Atherosclerosis Reports</i> , 2009, 11, 71-79.	4.8	32
113	Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2013, 7, S6-S10.	1.5	32
114	Comparing different assessments of remnant lipoprotein cholesterol: The very large database of lipids. <i>Journal of Clinical Lipidology</i> , 2019, 13, 634-644.	1.5	32
115	Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. <i>Journal of Clinical Lipidology</i> , 2014, 8, 107-116.	1.5	31
116	Novel Therapeutic Targets for Managing Dyslipidemia. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 733-747.	8.7	31
117	Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP). <i>Nutrition Research Reviews</i> , 2020, 33, 155-179.	4.1	31
118	Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia. <i>Current Pharmaceutical Design</i> , 2017, 23, 2496-2503.	1.9	31
119	The Relationship between COVID-19 and Hypothalamic—Pituitary—Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess—The CAPISCO International Expert Panel. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7326.	4.1	30
120	An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1248-1258.	1.5	29
121	Effect of Evolocumab on Lipoprotein Particles. <i>American Journal of Cardiology</i> , 2018, 121, 308-314.	1.6	29
122	Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. <i>Vascular Health and Risk Management</i> , 2013, 9, 719.	2.3	28
123	Drug safety evaluation of rosuvastatin. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 969-986.	2.4	27
124	Association Between Smoking and Serum GlycA and High-Sensitivity C-Reactive Protein Levels: The Multi-Ethnic Study of Atherosclerosis (MESA) and Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	27
125	Prevalence of potential familial hypercholesterolemia (FH) in 54,811 statin-treated patients in clinical practice. <i>Atherosclerosis</i> , 2016, 252, 1-8.	0.8	26
126	Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials. <i>Current Atherosclerosis Reports</i> , 2020, 22, 18.	4.8	26

#	ARTICLE	IF	CITATIONS
127	Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study. <i>Lipids in Health and Disease</i> , 2016, 15, 22.	3.0	25
128	Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. <i>Scientific Reports</i> , 2016, 6, 30060.	3.3	25
129	Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies. <i>Journal of the American Heart Association</i> , 2020, 9, e014129.	3.7	25
130	Antisense therapy and emerging applications for the management of dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2011, 5, 441-449.	1.5	24
131	Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy. <i>Vascular Health and Risk Management</i> , 2012, 8, 39.	2.3	24
132	HDL Hypothesis: Where Do We Stand Now?. <i>Current Atherosclerosis Reports</i> , 2014, 16, 398.	4.8	24
133	Bioresorbable scaffold "A magic bullet for the treatment of coronary artery disease?. <i>International Journal of Cardiology</i> , 2016, 215, 47-59.	1.7	24
134	Use of Microsomal Triglyceride Transfer Protein Inhibitors in Patients With Homozygous Familial Hypercholesterolemia: Translating Clinical Trial Experience Into Clinical Practice. <i>Reviews in Cardiovascular Medicine</i> , 2014, 15, 1-10.	1.4	24
135	High-density lipoprotein: Epidemiology, metabolism, and antiatherogenic effects. <i>Disease-a-Month</i> , 2001, 47, 365-416.	1.1	23
136	The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups. <i>Clinical Lipidology</i> , 2013, 8, 13-41.	0.4	23
137	Taking a longer term view of cardiovascular risk: the causal exposure paradigm. <i>BMJ</i> , The, 2014, 348, g3047-g3047.	6.0	23
138	Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies. <i>BMC Medicine</i> , 2021, 19, 139.	5.5	22
139	The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2017, 122, 105-117.	7.1	21
140	Adiponectin and high-density lipoprotein: a metabolic association through thick and thinThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. <i>European Heart Journal</i> , 2005, 26, 1579-1581.	2.2	20
141	Making a Case for Quantitative Assessment of Cardiovascular Risk. <i>Journal of Clinical Lipidology</i> , 2007, 1, 234-241.	1.5	19
142	A Commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia) Tj ETQq0 0 0 rgBT /Overlock 1 therapy for dyslipidemia?. <i>Journal of Clinical Lipidology</i> , 2008, 2, 313-317.	1.5	19
143	Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. <i>Journal of Clinical Lipidology</i> , 2012, 6, 180-191.	1.5	19
144	Relation of Fish Oil Supplementation to Markers of Atherothrombotic Risk in Patients With Cardiovascular Disease Not Receiving Lipid-Lowering Therapy. <i>American Journal of Cardiology</i> , 2015, 115, 1204-1211.	1.6	19

#	ARTICLE	IF	CITATIONS
145	A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients. <i>Pharmacological Research</i> , 2016, 111, 343-356.	7.1	19
146	The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGram2015 study. <i>Atherosclerosis Supplements</i> , 2020, 42, e15-e24.	1.2	18
147	Pasta Supplemented with <i>Opuntia ficus-indica</i> Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study. <i>Metabolites</i> , 2020, 10, 428.	2.9	17
148	Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2020, 155, 104719.	7.1	17
149	Activation of intracellular signaling systems by high-density lipoproteins. <i>Journal of Clinical Lipidology</i> , 2010, 4, 376-381.	1.5	16
150	Epicardial Steatosis, Insulin Resistance, and Coronary Artery Disease. <i>Heart Failure Clinics</i> , 2012, 8, 671-678.	2.1	16
151	Clinical and economic outcomes in a real-world population of patients with elevated triglyceride levels. <i>Atherosclerosis</i> , 2014, 237, 790-797.	0.8	16
152	PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. <i>Vascular Health and Risk Management</i> , 2016, 12, 185.	2.3	16
153	IMPROVE-IT. <i>Current Opinion in Cardiology</i> , 2016, 31, 426-433.	1.8	16
154	Cardiac CT angiography in current practice: An American society for preventive cardiology clinical practice statement. <i>American Journal of Preventive Cardiology</i> , 2022, 9, 100318.	3.0	16
155	Dysfunctional HDL: the journey from savior to slayer. <i>Clinical Lipidology</i> , 2014, 9, 49-59.	0.4	15
156	Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1703-1715.	2.6	15
157	An Update on the Benefits and Risks of Rosuvastatin Therapy. <i>Postgraduate Medicine</i> , 2014, 126, 7-17.	2.0	14
158	Screening and advanced lipid phenotyping in familial hypercholesterolemia: The Very Large Database of Lipids Study-17 (VLDL-17). <i>Journal of Clinical Lipidology</i> , 2015, 9, 676-683.	1.5	14
159	High-density Lipoprotein-cholesterol Subfractions and Coronary Artery Calcium: The ELSA-Brasil Study. <i>Archives of Medical Research</i> , 2019, 50, 362-367.	3.3	14
160	Elevated Triglycerides (≥ 150 mg/dL) and High Triglycerides (200–499 mg/dL) Are Significant Predictors of Hospitalization for New-Onset Kidney Disease: A Real-World Analysis of High-Risk Statin-Treated Patients. <i>CardioRenal Medicine</i> , 2019, 9, 400-407.	1.9	14
161	Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. <i>Future Cardiology</i> , 2021, 17, 155-174.	1.2	14
162	Contemporary Management of Dyslipidemia. <i>Drugs</i> , 2022, 82, 559-576.	10.9	14

#	ARTICLE	IF	CITATIONS
163	When high is low: Raising low levels of high-density lipoprotein cholesterol. Current Cardiology Reports, 2008, 10, 488-496.	2.9	13
164	Recommendations for the Management of Patients with Familial Hypercholesterolemia. Current Atherosclerosis Reports, 2015, 17, 473.	4.8	13
165	Statin combination therapy and cardiovascular risk reduction. Future Cardiology, 2016, 12, 289-315.	1.2	13
166	The effects of statin treatment on adrenal and sexual function and nitric oxide levels in hypercholesterolemic male patients treated with a statin. Journal of Clinical Lipidology, 2016, 10, 1452-1461.	1.5	13
167	<p>Elevated Triglycerides (≥150 mg/dL) and High Triglycerides (200–499 mg/dL) Are Significant Predictors of New Heart Failure Diagnosis: A Real-World Analysis of High-Risk Statin-Treated Patients</p>. Vascular Health and Risk Management, 2019, Volume 15, 533-538.	2.3	13
168	Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies. Journal of the American College of Cardiology, 2021, 78, 1437-1449.	2.8	13
169	Torcetrapib and atherosclerosis: what happened and where do we go from here?. Future Lipidology, 2007, 2, 277-284.	0.5	12
170	Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia. Clinical Therapeutics, 2016, 38, 603-609.	2.5	12
171	Changes in lipoprotein subfractions following menopause in the Longitudinal Study of Adult Health (ELSA-Brasil). Maturitas, 2019, 130, 32-37.	2.4	12
172	Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology. Trends in Cardiovascular Medicine, 2021, 31, 49-56.	4.9	12
173	The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease. Journal of Clinical Lipidology, 2014, 8, 594-605.	1.5	11
174	Modern prevalence of the Fredrickson-Levy-Lees dyslipidemias: findings from the Very Large Database of Lipids and National Health and Nutrition Examination Survey. Archives of Medical Science, 2020, 16, 1279-1287.	0.9	11
175	Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial. Cardiovascular Diabetology, 2021, 20, 125.	6.8	11
176	CAC for Risk Stratification Among Individuals With Hypertriglyceridemia Free of Clinical Atherosclerotic Cardiovascular Disease. JACC: Cardiovascular Imaging, 2022, 15, 641-651.	5.3	11
177	Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. Vascular Health and Risk Management, 2010, 6, 1065.	2.3	10
178	Statin therapy and inflammation in patients with diabetes treated with high dose aspirin. Journal of Diabetes and Its Complications, 2016, 30, 1365-1370.	2.3	10
179	Association between high-density lipoprotein subfractions and low-grade inflammation, insulin resistance, and metabolic syndrome components: The ELSA-Brasil study. Journal of Clinical Lipidology, 2018, 12, 1290-1297.e1.	1.5	10
180	The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy. Journal of Clinical Lipidology, 2019, 13, 754-761.	1.5	10

#	ARTICLE	IF	CITATIONS
181	Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in high-risk statin-treated patients: A large administrative retrospective analysis. <i>Clinical Cardiology</i> , 2019, 42, 908-913.	1.8	10
182	Impact of improved low-density lipoprotein cholesterol assessment on guideline classification in the modern treatment era—Results from a racially diverse Brazilian cross-sectional study. <i>Journal of Clinical Lipidology</i> , 2019, 13, 804-811.e2.	1.5	10
183	Targeting hypertriglyceridemia to mitigate cardiovascular risk: A review. <i>American Journal of Preventive Cardiology</i> , 2020, 3, 100086.	3.0	10
184	REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	10
185	Is HPS2-THRIVE the death knell for niacin?. <i>Journal of Clinical Lipidology</i> , 2015, 9, 343-350.	1.5	9
186	Spotlight from the American Society for Preventive Cardiology on Key Features of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 1-9.	2.2	9
187	Ten things to know about ten imaging studies: A preventive cardiology perspective (â€œASPC top ten) Tj ETQq1 1 0,784314,rgBT /Over	3.0	9
188	Design and rationale of a nationwide screening analysis from the LIPIDOGRAM2015 and LIPIDOGEN2015 studies. <i>Archives of Medical Science</i> , 2020, 18, 604-616.	0.9	9
189	The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5656.	2.4	9
190	Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction. <i>American Journal of Cardiology</i> , 2016, 118, 19A-32A.	1.6	8
191	All-Cause and Acute Pancreatitis Health Care Costs in Patients With Severe Hypertriglyceridemia. <i>Pancreas</i> , 2017, 46, 57-63.	1.1	8
192	Therapeutic effects of statins on chromosomal DNA damage of dyslipidemic patients. <i>Experimental Biology and Medicine</i> , 2019, 244, 1089-1095.	2.4	8
193	Composite acute phase glycoproteins with coronary artery calcification depends on metabolic syndrome presence â€œ The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Journal of Cardiology</i> , 2019, 73, 408-415.	1.9	8
194	Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMd dyslipidemia study). <i>Lipids in Health and Disease</i> , 2020, 19, 237.	3.0	8
195	Heart failure with preserved ejection fraction: strategies for disease management and emerging therapeutic approaches. <i>Postgraduate Medicine</i> , 2021, 133, 125-139.	2.0	8
196	Heart failure with preserved ejection fraction: disease burden for patients, caregivers, and the health-care system. <i>Postgraduate Medicine</i> , 2021, 133, 140-145.	2.0	8
197	Branched-chain amino acids predict incident diabetes in the Brazilian Longitudinal Study of Adult Health â€œ ELSA-Brasil. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108747.	2.8	8
198	Real-world analyses of patients with elevated atherosclerotic cardiovascular disease risk from the Optum Research Database. <i>Future Cardiology</i> , 2021, 17, 743-755.	1.2	8

#	ARTICLE	IF	CITATIONS
199	Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)-Free Low-Density Lipoprotein Cholesterol. <i>Journal of the American Heart Association</i> , 2022, 11, e023136.	3.7	8
200	Pleiotropic Effects of Angiotensin Receptor Blockers: Addressing Comorbidities by Optimizing Hypertension Therapy. <i>Journal of Clinical Hypertension</i> , 2011, 13, 42-51.	2.0	7
201	Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia. <i>American Journal of Cardiology</i> , 2016, 118, 1812-1820.	1.6	7
202	Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGH trial. <i>Journal of Clinical Lipidology</i> , 2018, 12, 741-747.e11.	1.5	6
203	Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapy. <i>Journal of Clinical Lipidology</i> , 2019, 13, 997-1007.e8.	1.5	6
204	That Myalgia of Yours Is Not From Statin Intolerance. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1223-1226.	2.8	6
205	Weight loss programmes using low carbohydrate diets to control the cardiovascular risk in adolescents (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 90.	1.8	6
206	Prevalence of United States adults with triglycerides ≥ 135 mg/dL: NHANES 2007-2014. <i>Cardiology Journal</i> , 2019, 26, 604-606.	1.2	6
207	An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Atherosclerosis: the underlying disease. <i>Journal of Family Practice</i> , 2009, 58, S19-25.	0.2	6
208	The Potential Role of Prasugrel in Secondary Prevention of Ischemic Events in Patients with Acute Coronary Syndromes. <i>Postgraduate Medicine</i> , 2009, 121, 59-72.	2.0	5
209	Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The very large database of lipids-9. <i>Journal of Clinical Lipidology</i> , 2015, 9, 511-518.e5.	1.5	5
210	Implications of the New US Cholesterol Guidelines in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Clinical Cardiology</i> , 2016, 39, 215-222.	1.8	5
211	PCSK9 and Lipoprotein(a). <i>Circulation Research</i> , 2016, 119, 3-6.	4.5	5
212	Lipid-lowering treatment modifications among patients with hyperlipidemia and a prior cardiovascular event: a US retrospective cohort study. <i>Current Medical Research and Opinion</i> , 2017, 33, 869-876.	1.9	5
213	Relation Between Cardiology Follow-Up Visits, Evidence-Based Statin Prescribing, and Statin Adherence (from the Veterans Affairs Health Care System). <i>American Journal of Cardiology</i> , 2019, 124, 1165-1170.	1.6	5
214	Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study. <i>Rheumatology International</i> , 2022, 42, 261-271.	3.0	5
215	Effective Management of the Type 2 Diabetes Patient with Cardiovascular and Renal Disease: Secondary Prevention Strategies after a Myocardial Infarction. <i>Current Diabetes Reviews</i> , 2012, 8, 219-228.	1.3	4
216	Glucolipotoxicity and the Heart. <i>Heart Failure Clinics</i> , 2012, 8, xvii-xviii.	2.1	4

#	ARTICLE	IF	CITATIONS
217	JCL Roundtable: HDL in the primary care setting. Journal of Clinical Lipidology, 2014, 8, 364-372.	1.5	4
218	Treatment of Dyslipidemia in Elderly Patients With Coronary Heart Disease. Journal of the American College of Cardiology, 2015, 66, 1873-1875.	2.8	4
219	Differences in HDL particle size in the presence of subclinical thyroid dysfunctions: The ELSA-Brasil study. Atherosclerosis, 2020, 312, 60-65.	0.8	4
220	Unfavorable Triglyceride-rich Particle Profile in Subclinical Thyroid Disease: A Cross-sectional Analysis of ELSA-Brasil. Endocrinology, 2021, 162, .	2.8	4
221	Low-Density Lipoprotein Cholesterol Treatment Rates in High Risk Patients: More Disappointment Despite Ever More Refined Evidence-Based Guidelines.. American Journal of Preventive Cardiology, 2021, 6, 100186.	3.0	4
222	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE). Archivos De Cardiologia De Mexico, 2021, 92, .	0.2	4
223	High-dose statin therapy: benefits and safety in aggressive lipid lowering. Journal of Family Practice, 2008, 57, S29-36.	0.2	4
224	Differentiating EPA from EPA/DHA in cardiovascular risk reduction. American Heart Journal Plus, 2022, 17, 100148.	0.6	4
225	Management of pregnancy-related hypertensive disorders in patients infected with SARS CoV-2: pharmacological and clinical issues. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 346-351.	3.0	3
226	Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007â€“2014. American Journal of Preventive Cardiology, 2020, 3, 100087.	3.0	3
227	Is the Guideline Process Replicable and, if Not, What Does This Mean?. Progress in Cardiovascular Diseases, 2015, 58, 3-9.	3.1	2
228	INCREASED RESIDUAL CARDIOVASCULAR RISK IN US VETERANS AND MONERATELY-ELEVATED BASELINE TRIGLYCERIDES AND WELL-CONTROLLED LDL-C LEVELS ON STATINS. Journal of the American College of Cardiology, 2019, 73, 1719.	2.8	2
229	Lipoprotein Subfractions in Patients with Acute Coronary Syndromes: Should we Reach Beyond LDL-C?. Current Vascular Pharmacology, 2019, 17, 376-378.	1.7	2
230	Familial Hypercholesterolemia andÂLipoprotein(a). Journal of the American College of Cardiology, 2020, 75, 2694-2697.	2.8	2
231	An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Commentary. Journal of Family Practice, 2009, 58, S41-3.	0.2	2
232	Stroke Prevention in Patients With Atrial Fibrillation: Focus on New Oral Anticoagulants. Postgraduate Medicine, 2013, 125, 155-161.	2.0	1
233	Direct oral anticoagulants as alternative treatment options for the effective long-term treatment of patients with pulmonary embolism in primary care: a review. Annals of Medicine, 2014, 46, 341-352.	3.8	1
234	Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom?. , 2015, , 179-190.		1

#	ARTICLE	IF	CITATIONS
235	Baseline Characteristics of a Retrospective Claims Analysis of Cardiovascular Outcomes and Health Care Resource Utilization and Costs in High-Risk Statin-Treated Patients With Hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2017, 11, 797.	1.5	1
236	Identification and treatment of those most at risk for premature atherosclerotic cardiovascular disease: We just cannot seem to get it right. <i>American Journal of Preventive Cardiology</i> , 2020, 2, 100040.	3.0	1
237	Recommendations of statin treatment after acute coronary syndrome: Hungarian experiences. <i>Atherosclerosis</i> , 2020, 303, 53-54.	0.8	1
238	Statin Prescribing and Dosing—Failure Has Become an Option. <i>JAMA Cardiology</i> , 2021, 6, 854.	6.1	1
239	Atherogenesis and Vascular Biology. <i>Contemporary Cardiology</i> , 2021, , 11-34.	0.1	1
240	Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress. <i>Biomarker Insights</i> , 2022, 17, 117727192110667.	2.5	1
241	An Urgent Matter. Identifying Your Patients' Cardiovascular Risk and Improving Their Outcomes. Introduction. <i>Journal of Family Practice</i> , 2009, 58, S17-8.	0.2	1
242	What is sufficient drug therapy for lipoprotein elevations?. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1300-1308.	1.5	0
243	Response to “Trends in Obesity, NHANES 2003–2004 to 2013–2014: Is Waist Circumference Increasing Independently of Body Mass Index?” <i>Obesity</i> , 2019, 27, 1044.	3.0	0
244	Management of Dyslipidemia. <i>Contemporary Cardiology</i> , 2019, , 39-69.	0.1	0
245	Cover Image, Volume 22, Issue 3. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, .	4.4	0
246	Cardiovascular Disease Epidemiology and Risk Factors: General Concepts. <i>Contemporary Cardiology</i> , 2021, , 1-22.	0.1	0
247	ASPC President’s Page: Addressing Unmet Needs in Preventive Cardiology. <i>American Journal of Preventive Cardiology</i> , 2021, 5, 100155.	3.0	0
248	INCREASED INPATIENT MORTALITY FOR CARDIOVASCULAR PATIENTS DURING THE FIRST WAVE OF THE COVID-19 EPIDEMIC IN NEW YORK. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3042.	2.8	0
249	ASPC President's Page: Advancing and Refining Cardiovascular Disease Prevention. <i>American Journal of Preventive Cardiology</i> , 2021, 6, 100194.	3.0	0
250	Celebrating ASPC's achievements and introducing new educational offerings. <i>American Journal of Preventive Cardiology</i> , 2021, 7, 100226.	3.0	0
251	Proprotein Convertase Subtilisin/Kexin Type 9: Functional Role in Lipid Metabolism and Its Therapeutic Inhibition. <i>Contemporary Cardiology</i> , 2021, , 269-294.	0.1	0
252	The bandwidth of preventive cardiology continues to increase: Meeting the challenge head on. <i>American Journal of Preventive Cardiology</i> , 2020, 4, 100132.	3.0	0

#	ARTICLE	IF	CITATIONS
253	Addressing key questions with statin therapy. Journal of Family Practice, 2012, 61, S34-9.	0.2	0
254	Hot Topics in Primary Care: Familial Hypercholesterolemia in Youth. Journal of Family Practice, 2015, 64, S22-30.	0.2	0
255	Substantially elevated TSH, not traditional clinical subclinical thyroid disorder groupings, are associated with smaller LDL-P mean size: ELSA-Brasil. Journal of Clinical Lipidology, 2022, , .	1.5	0
256	President's page: ASCP is leading the way in preventive cardiology. American Journal of Preventive Cardiology, 2022, 9, 100321.	3.0	0
257	ASPC President's Page: Getting back To Basics One Patient at a Time. American Journal of Preventive Cardiology, 2022, , 100350.	3.0	0